Jeremy Barton
Nessuna posizione attualmente
Profilo
Jeremy Barton joined Seattle Genetics in November 2004.
In his role as Senior Medical Director, Dr. Barton is responsible for the clinical development activities of a number of the company's product candidates.
Prior to joining Seattle Genetics, he was a clinical development consultant to multiple biotechnology companies in the United Kingdom.
Previously, Dr. Barton was with Millennium Pharmaceuticals in London as Director of Clinical Research, Oncology, where he was involved in European drug development and commercialization activities.
Before that, he held senior clinical research positions at Elan Pharmaceuticals, Astra Zeneca and Glaxo Wellcome covering all phases of oncology drug development, working with cytotoxics, biologicals and signal transduction inhibitors.
Dr. Barton received his medical training at Oxford University and at University College Hospital Medical School in London.
His post graduate experience is in internal medicine and clinical oncology and he is board certified in medical oncology and radiation oncology.
Dr. Barton is a member of the Royal College of Physicians in the U.K.
and is a fellow of the Royal College of Radiologists
Precedenti posizioni note di Jeremy Barton
Società | Posizione | Fine |
---|---|---|
SEAGEN INC. | Direttore Tecnico/Scientifico/R&S | - |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
Aziende private | 1 |
---|---|
Seagen Inc.
Seagen Inc. Pharmaceuticals: MajorHealth Technology Seagen Inc. is a biotechnology company, which engages in the development and commercialization of targeted therapies for the treatment of cancer. It also focuses on the advancement of therapies for solid tumors and blood-related cancers. Its products include Adcetris, Padcev, Tivdak, and Tukysa. The company was founded by Clay B. Siegall and H. Perry Fell on July 15, 1997 and is headquartered in Bothell, WA. | Health Technology |
- Borsa valori
- Insiders
- Jeremy Barton